FDA Adds Vision Loss Warning to Ozempic, Zepbound

Last updated November 15, 2026
The FDA will add a warning about a rare eye condition to Ozempic, Wegovy, Zepbound and other GLP-1 drugs. Here is how rare it is and what signs to watch.
Key Points
- The Food and Drug Administration (FDA) announced the warning on November 9.
- It covers a rare condition that cuts blood flow to the optic nerve.
- In trials, it affected about 6 in 100,000 people taking a GLP-1 drug for a year or more.
- Call a doctor right away for blurry vision, blind spots or color changes.
What the FDA Announced
All GLP-1 drugs will get a new label warning about an eye condition called NAION. That stands for non-arteritic anterior ischemic optic neuropathy, CBS News reported.
The drugs include Ozempic and Wegovy from Novo Nordisk, and Zepbound and Mounjaro from Eli Lilly.
The FDA review began after a 2024 medical paper linked the condition to some people taking semaglutide.
The Numbers So Far
| Fact | Figure | Source |
|---|---|---|
| Warning announced | November 9, 2026 | CBS News |
| Trials reviewed | More than 125 | CBS News |
| NAION rate on GLP-1 drugs | About 6 per 100,000 | CBS News |
| Rate on placebo or other drugs | Under 4 per 100,000 | CBS News |
| Drugs named | Ozempic, Wegovy, Zepbound, Mounjaro | U.S. News |
What Is NAION?
NAION happens when blood flow to the optic nerve drops. It can cause serious vision loss that is sometimes permanent.
People who do not take GLP-1 drugs can get it too. It affects about 2 to 10 in 100,000 adults over 50. That estimate is from the American Academy of Ophthalmology, as cited by CBS News.
Claim vs Fact
| Claim you may hear | What the record shows |
|---|---|
| GLP-1 drugs make many people go blind | NAION is rare, about 6 in 100,000 users in trials |
| The FDA banned Ozempic | The FDA added a label warning, it did not pull the drugs |
| Drug makers agree it causes NAION | Novo Nordisk says the data do not prove it |
Does this warning change how you feel about GLP-1 drugs?
- Yes, I am more worried
- No, the risk seems small
- I will ask my doctor
- Not sure
Free updates
Join the Digieh list
Be the first to know when our weekly brief launches.
No spam. Unsubscribe anytime. Read our Privacy Policy.
What the Drug Makers Say
Novo Nordisk said the data do not establish a cause-and-effect relationship. Eli Lilly said it is carefully evaluating the update, per CBS News.
The news was also reported by Reuters via U.S. News.
Why It Matters
Millions of people take GLP-1 drugs for diabetes or weight loss. The warning helps patients and doctors spot eye problems early.
New to these drugs? Read our guide to GLP-1 medicines explained. Screen time can also strain eyes, so see our tips on how to reduce eye strain.
When to Get Help
Contact a doctor right away if you take a GLP-1 drug and notice any of these signs, the FDA says.
- Blurred vision
- Blind spots
- Colors that look faded or wrong
- Any sudden change in vision
Do not stop your medicine on your own. Talk with your doctor first. This article is for information only and is not medical advice.
- Know the warning signs of NAION
- Report vision changes to your doctor right away
- Keep up with regular eye exams
- Do not stop medicine without medical advice
What did the FDA do on November 9?
- Banned GLP-1 drugs
- Recalled Ozempic
- Ordered a new eye risk warning on labels
The FDA ordered a label warning about NAION for all GLP-1 drugs.
Frequently Asked Questions
Does Ozempic cause vision loss?
The FDA added a warning about NAION, a rare eye condition. Novo Nordisk says the data do not prove the drug causes it.
How rare is NAION with GLP-1 drugs?
An FDA review of trials found about 6 cases per 100,000 patients. Those patients took a GLP-1 drug for at least a year.
Should I stop taking my GLP-1 medicine?
Do not stop on your own. Talk with your doctor, and report any vision changes right away.
Found this useful?
Editor’s Note
This story is accurate as of November 15, 2026. It is based on the FDA announcement as reported by CBS News and Reuters. It is not medical advice.
Spot an error in this article? Please contact us at support@digieh.com or read our Corrections Policy.
Keep exploring
Your next read is waiting
1TechnologyHow to Add a Text or Logo Watermark to a PDF7 min read
2HealthThe Vital Truth About Losing Measles Elimination Status5 min read
3NewsFAA Ground Stop and Your Essential Refund Rights5 min read
4EcommerceReal Etsy Fees and How Much You Keep5 min read
5Pets & AnimalsThanksgiving Foods That Are Dangerous for Your Pets4 min read
6Food & LifestyleTurkey Cooking Time by Weight, the Easy Chart4 min read











